JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer.

[1]  W. Sellers,et al.  Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent. , 2012, Cancer discovery.

[2]  A. Jimeno,et al.  JAK2 inhibition for the treatment of hematologic and solid malignancies , 2012, Expert opinion on investigational drugs.

[3]  Francisco Cervantes,et al.  JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.

[4]  Gordon B Mills,et al.  Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. , 2012, Cancer cell.

[5]  R. Figlin,et al.  Antiangiogenic and antimetastatic activity of JAK inhibitor AZD1480. , 2011, Cancer research.

[6]  W. Sellers.  A Blueprint for Advancing Genetics-Based Cancer Therapy , 2011, Cell.

[7]  Mithat Gönen,et al.  The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.

[8]  J. Baselga,et al.  The Evolving War on Cancer , 2011, Cell.

[9]  N. Rosen,et al.  Resistance to BRAF inhibition in melanomas. , 2011, The New England journal of medicine.

[10]  J. Campisi,et al.  Four faces of cellular senescence , 2011, The Journal of cell biology.

[11]  Sarat Chandarlapaty,et al.  AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity. , 2011, Cancer cell.

[12]  K. Flaherty,et al.  Inhibition of mutated, activated BRAF in metastatic melanoma. , 2010, The New England journal of medicine.

[13]  D. Erdmann,et al.  Potent and Selective Inhibition of Polycythemia by the Quinoxaline JAK2 Inhibitor NVP-BSK805 , 2010, Molecular Cancer Therapeutics.

[14]  D. Birnbaum,et al.  CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. , 2010, The Journal of clinical investigation.

[15]  Luca Toschi,et al.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. , 2010, Cancer cell.

[16]  H. Lane,et al.  Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells , 2009, Proceedings of the National Academy of Sciences.

[17]  Hua Yu,et al.  The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. , 2009, Cancer cell.

[18]  Kwok-Kin Wong,et al.  Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition , 2009, Proceedings of the National Academy of Sciences.

[19]  J. Asara,et al.  Characterization of Rictor Phosphorylation Sites Reveals Direct Regulation of mTOR Complex 2 by S6K1 , 2009, Molecular and Cellular Biology.

[20]  Wan-chi Lin,et al.  Targeting janus kinase 2 in Her2/neu-expressing mammary cancer: Implications for cancer prevention and therapy. , 2009, Cancer research.

[21]  Jeffrey A. Engelman,et al.  Targeting PI3K signalling in cancer: opportunities, challenges and limitations , 2009, Nature Reviews Cancer.

[22]  W. Sellers,et al.  PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. , 2009, Cancer research.

[23]  F. Bertucci,et al.  Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. , 2009, Cancer research.

[24]  Ralph Weissleder,et al.  Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.

[25]  D. Waugh,et al.  The Interleukin-8 Pathway in Cancer , 2008, Clinical Cancer Research.

[26]  J. Baselga,et al.  NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. , 2008, Cancer research.

[27]  C. Carter-Su,et al.  JAK2, but not Src family kinases, is required for STAT, ERK, and Akt signaling in response to growth hormone in preadipocytes and hepatoma cells. , 2008, Molecular endocrinology.

[28]  Daniela Gabriel,et al.  Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity , 2008, Molecular Cancer Therapeutics.

[29]  P. Jänne,et al.  Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[30]  G. Mills,et al.  Improved classification of breast cancer by analysis of genetic alterations and gene expression profiling , 2011 .

[31]  Govind Bhagat,et al.  Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia , 2007, Nature Medicine.

[32]  Ceri M. Wiggins,et al.  ERK1/2‐dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl‐1 and Bcl‐xL , 2007, The EMBO journal.

[33]  Wen-Lin Kuo,et al.  A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. , 2006, Cancer cell.

[34]  B. Groner,et al.  The Biological Functions of the Versatile Transcription Factors STAT3 and STAT5 and New Strategies for their Targeted Inhibition , 2006, Journal of Mammary Gland Biology and Neoplasia.

[35]  Ji Luo,et al.  The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.

[36]  J. Opferman.  Unraveling MCL-1 degradation , 2006, Cell Death and Differentiation.

[37]  S. Armstrong,et al.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. , 2006, Cancer cell.

[38]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[39]  A. Newton,et al.  PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. , 2005, Molecular cell.

[40]  Pietro Ghezzi,et al.  Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[41]  I. Gout,et al.  The TSC1-2 tumor suppressor controls insulin–PI3K signaling via regulation of IRS proteins , 2004, The Journal of cell biology.

[42]  J. Mestan,et al.  AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. , 2004, Cancer research.

[43]  J. Ptak,et al.  High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.

[44]  S. Cook,et al.  Activation of the ERK1/2 Signaling Pathway Promotes Phosphorylation and Proteasome-dependent Degradation of the BH3-only Protein, Bim* , 2003, Journal of Biological Chemistry.

[45]  Francisco Cervantes,et al.  Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. , 2003, The New England journal of medicine.

[46]  R. Kohanski,et al.  Dual mechanism of signal transducer and activator of transcription 5 activation by the insulin receptor. , 2002, Molecular endocrinology.

[47]  G. Thomas,et al.  Lethality of Drosophila lacking TSC tumor suppressor function rescued by reducing dS6K signaling. , 2002, Genes & development.

[48]  Mina J. Bissell,et al.  Putting tumours in context , 2001, Nature Reviews Cancer.

[49]  J. Olefsky,et al.  A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1. , 2000, Molecular endocrinology.

[50]  G. Stark,et al.  Growth Hormone and Prolactin Stimulate Tyrosine Phosphorylation of Insulin Receptor Substrate-1, -2, and -3, Their Association with p85 Phosphatidylinositol 3-Kinase (PI3-kinase), and Concomitantly PI3-kinase Activation via JAK2 Kinase* , 1998, The Journal of Biological Chemistry.

[51]  E. Van Obberghen,et al.  Interaction of Janus Kinases JAK-1 and JAK-2 with the Insulin Receptor and the Insulin-Like Growth Factor-1 Receptor. , 1998, Endocrinology.

[52]  Kohjiro Ueki,et al.  Tyrosine phosphorylation of the EGF receptor by the kinase Jak2 is induced by growth hormone , 1997, Nature.

[53]  R. Clarke.  Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models , 1997, Breast Cancer Research and Treatment.

[54]  R. Pearson,et al.  Targeting PI3 kinase/AKT/mTOR signaling in cancer. , 2012, Critical reviews in oncogenesis.

[55]  C. Hudis,et al.  Triple-negative breast cancer: an unmet medical need. , 2011, The oncologist.

[56]  Maira Sauveur-Michel,et al.  HER2が増幅されPI3K3CAが変異した乳癌細胞におけるPI3K/mTor二重阻害剤NVP‐BEZ235による特異的アポトーシス誘発 , 2009 .

[57]  B. Hemmings,et al.  PKB and the mitochondria: AKTing on apoptosis. , 2008, Cellular signalling.

[58]  N. Hanna,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2008 .